Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
Launched by PFIZER · May 14, 2013
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
retrospective and prospective 150
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • retrospective:12 months at least first anti-TNF therapy prospective: at maximum 6 months observation AS patients with axial involvement
- Exclusion Criteria:
- • patients in other AS studies involved
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Torino, , Italy
Udine, , Italy
Roma, , Italy
Milano, , Italy
Padova, , Italy
Catania, Ct, Italy
Bologna, , Italy
Brescia, , Italy
Cagliari, , Italy
Ferrara, , Italy
Firenze, , Italy
Milano, , Italy
Napoli, , Italy
Palermo, , Italy
Palermo, , Italy
Prato, , Italy
Roma, , Italy
Verona, , Italy
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials